Recombinant Human GLA
Contáctenos para saber el precio
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Recombinant Human GLA
category
Proteins and Peptides
provider
FineTest
reference
P0494
tested applications
Western Blot, ELISA
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Host | E.Coli |
| Reactivity | Human |
| Assay Data | Centrifuge the vial before opening, reconstitute in sterile distilled water to a concentration of 0.1-1 mg/ml by gently pipetting 2-3 times, don't vortex. |
| Observed MW | 30.4 kDa |
| Expression | 322-409 |
| Purity | Greater than 90% as determined by SDS-PAGE. |
| Size 1 | 50μg |
| Size 2 | 200μg |
| Size 3 | 1mg |
| Form | Lyophilized powder |
| Tested Applications | Western Blot, ELISA |
| Buffer | Lyophilized from a 0.2 μm filtered solution in 10 mM Hepes, 500 mM NaCl with 5% trehalose, pH 7.4. |
| Availability | 7 days |
| Storage | The lyophilized protein is stable at -20 °C for up to 1 year. After reconstitution, the protein solution is stable at -20 to -80 °C for 3 months or 1 week at 2 to 8 °C under sterile conditions. For extended storage, it is recommended to further dilute in working aliquots, avoid repeated freeze/thaw cycle. |
| UniProt ID | P06280 |
| Alias | agalsidase alfa, Agalsidase alpha, Agalsidase, Alpha-D-galactosidase A, alpha-D-galactoside galactohydrolase 1, Alpha-D-galactoside galactohydrolase, alpha-gal A, alpha-galactosidase A, EC 3.2.1, EC 3.2.1.22, GALA, galactosidase, alpha, GLA, Melibiase |
| Background | Protein GLA |
| Status | RUO |
| Note | Tag : N-terminal His-IF2DI Tag |
Related Products
Human GLA (Alpha-galactosidase A) ELISA Kit
Ver Producto
Porcine GLA (Alpha-galactosidase A) ELISA Kit
Ver Producto
GLA antibody
GLA, also named as Melibiase, Agalsidas and Alpha-galactosidase A, Belongs to the glycosyl hydrolase 27 family. It hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy(ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.
Ver Producto